Skip to main content

Table 1 FLT3 mutations among 517 acute leukemia subjects from the Northern California Childhood Leukemia Study

From: FLT3mutation incidence and timing of origin in a population case series of pediatric leukemia

Patient ID ITD or MUT* MUT Age Cytogenetics FAB (lineage) Backtrack result
0004 ITD   6.1 46, XY [10/20]; 46, XY, del(9)(p13) [9/20]; 47, XY, +?22 [1/20] ALL neg
0087 ITD   10.5 46, XY [21/24] AML-M1 neg
0104 ITD   9.1 46, XY [19/20]; 44, XY, -14, -22 [1/20] ALL-L1 (T-cell) neg
0126 ITD   14.9 46, XX [20/20] AML-M2  
0201 MUT GAT→GAA D835E 13.2 46, XY [20/20] AML-M2  
0261 ITD   13.7 46, XX, t(6;9)(p23;q34) [23/24] AML-M2 neg
0544 MUT GAT→GTT D835V 5.3 46, XX [20/20]; nuc ish 12p13(TEL×2), 21q22(AML1×4) [149/207]/12p13(TEL×2), 21q22(AML×2) [31/207]/12p13(TEL×2), 21q22(AML1×3) [25/207] ALL neg
0678 ITD   14.5 46, XX [20] AML-M2  
0738 MUT TAT→TGT Y842C 5.0 45, XY, -7, del(13)(q13q21) [12/20]; 46, XY [8/20] ALL-L1  
0745 MUT GAT→TAT D835Y 12.7 46, XY [21/21]; nuc ish 4cen(CEP4×2),
10cen(CEP10×2), 12p13(TEL×2), 21q22(AML1×2)
ALL-L1/L2  
0796 MUT GAT→TAT D835Y 1.8 46, XY [3/3]; nuc ish 12p13 (TEL×3), 21q22(AML1×4) [90/100], 12p13(TEL×2), 21q22(AML1×2) [10/100] FISH: +12++21/++X (presumed cryptic high hyperdiploidy) ALL-L1 neg
0803 MUT GAT→TAT D835Y and GAT→CAT D835H 0.3 46, XY [20/20]; nuc ish 11q23 (MLL5'x2, MLL3'x2) [200/200] AML-M5  
0945 MUT GAT→TAT D835Y 7.9 46, XY [21/21] ALL neg
0999 ITD   8.3 46, XX [20] AML  
1043 MUT GAT→CAT D835H 14.0 46, XY, inv(16)(p12q22) [12/12] AML  
1073 DEL   5.9 46, XY [30]; nuc ish 9q34(ABL×2), 22q11.2(BCR×2) ALL neg
1107 ‡§ MUT GAT→GCT D835A 3.5 56~58, XY, dup(1)(q21q32),+4,+5,+6,+10,+14,+18,+18,+19,+21, +22,+2mar [5/23]; 46, XY [18/23] ALL-L1  
1148 ITD   14.5 47, XX, +14 [16] AML neg
  1. ITD, internal tandem duplication; MUT, point mutation; DEL, deletion.
  2. neg: 240 ng of patient Guthrie card was tested and was determined to be negative. The rest of the patients were not tested.
  3. Patients exhibiting high hyperdiploidy by FISH assay (see Materials and Methods)
  4. §Patient 1107 has a KRAS mutation, which was also negative in backtracking experiment (ref #23)